Skip to content
Companies

EnZeta Immunotherapies

Engineered T-cell therapies for solid tumors

  • Coral Gables, FL
  • Founded 2023
  • Biotech

Raised to date

$840K

of $2.4M offered across 1 Form D filing

Still open
$1.5M
Investors
10
Last filed
Mar 6, 2026

About

EnZeta Immunotherapies is an early-stage biotechnology company founded in 2023 and headquartered in Coral Gables, Florida. The company focuses on developing and commercializing T-cell-based immunotherapies for the treatment of solid tumors. Its core strategy is built upon an exclusive patent license secured from the National Institutes of Health (NIH).

The company's primary strategic asset is its exclusive patent license from the NIH, providing it with foundational intellectual property to develop novel T-cell therapies for solid tumors.

Funding

  • EquityFiled Mar 6, 2026Form D/A
    $840K/ $2.4M

Product

T-cell-based Immunotherapies for Solid Tumors

Cancer Immunotherapy

The company is developing treatments that use a patient's own T cells, which are engineered to recognize and attack specific proteins on the surface of solid tumor cells. This therapeutic approach is based on technology covered by an exclusive patent license from the National Institutes of Health.

  • Engineered T-cell technology
  • Targeted treatment for solid tumors
  • Leverages government-backed intellectual property

Built for

The primary end-users for the company's therapies are patients diagnosed with various forms of solid tumors. The direct customers would include oncology departments in hospitals and specialized cancer treatment centers.

People on file